DBV Technologies Company Profile
DBV Technologies (DBV) is a speciality pharma company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergy diagnosis and treatment. The Company is lead by CEO Jean-François Biry and was born out of the experience of Professor Christophe Dupont, a paediatric GI, from Assistance Publique-Hôpitaux de Paris and Université Paris Descartes, Doctor Pierre-Henri Benhamou, a paediatrician specialising in gastro-enterology, allergosis and nutrition, and Bertrand Dupont, a qualified engineer from the Arts et Métiers Institute. DBV Technologies’ lead product, Diallertest® Milk, is on sale in France and other countries for the diagnosis of cow’s milk protein allergy.
DBV closed a €6million (EUR) Series B investment in January 2009 with new investor ALK-Abello, a leading worldwide immunotherapy company, and returning investor Sofinnova Partners.
DBV Technologies was founded in 2002 and is based in the Pépinière Paris Santé Cochin, in Paris’ 14th arrondissement.
Pépinière Paris Santé Cochin
29 rue du Faubourg Saint Jacques
Phone: +33 (0)1 55 42 78 78
Fax: +33 (0)1 43 26 10 83
Drugs and Medications
More Information about "DBV Technologies" on BioPortfolio
We have published hundreds of DBV Technologies news stories on BioPortfolio along with dozens of DBV Technologies Clinical Trials and PubMed Articles about DBV Technologies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of DBV Technologies Companies in our database. You can also find out about relevant DBV Technologies Drugs and Medications on this site too.